On November 4, 2024, Anapol Weiss attorneys Tracy Finken Magnotta and Tom Anapol will be presenting as part of the HarrisMartin Webinar Series: Depo-Provera CI Litigation. Their presentation, titled "Epidemiology of Depo-Provera and Other Progesterones, The Incidence of Meningioma in the Population," will explore epidemiological data connecting the use of Depo-Provera and other progesterone-based treatments with an increased incidence of meningioma.
The webinar will take place from 2:00 p.m. to 3:30 p.m. EST and offers CLE credit for attendees. This important presentation will delve into the risks associated with long-term use of Depo-Provera, a contraceptive injection, and the emerging evidence linking it to the development of meningiomas—tumors that form in the membranes surrounding the brain and spinal cord.
Why Attend? Finken Magnotta and Anapol will provide an analysis of the scientific research, legal precedents, and ongoing litigation regarding Depo-Provera. This presentation is essential for attorneys, healthcare professionals, and individuals affected by this issue, as it highlights both the medical and legal ramifications of the drug’s use.
Event Details:
- Date: November 4, 2024
- Time: 2:00 p.m. – 3:30 p.m. EST
- Location: HarrisMartin Webinar (Virtual Event)
- CLE Credit: Available for attending
To register for the event, visit the official HarrisMartin conference page here.
About the Speakers
- Tracy Finken Magnotta is an experienced attorney at Anapol Weiss with a focus on pharmaceutical litigation, particularly in cases involving harmful side effects from medications. She has been at the forefront of several major mass tort cases and has a deep understanding of the science and law related to drug safety.
- Tom Anapol is a co-founding partner of Anapol Weiss and has dedicated his career to representing individuals injured by defective drugs and medical devices. His legal expertise and commitment to justice have helped secure significant settlements and verdicts for clients nationwide.
This presentation is a critical opportunity to stay informed about the evolving litigation landscape surrounding Depo-Provera and similar drugs. We encourage anyone interested in this area of law to register and attend.
